Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 43 unusual trades. Delving into the details, we found 16% of traders were bullish, while 53% showed bearish ...

Me (OTC:MEHCQ) faces a second auction after a $305M bid challenges Regeneron's (REGN) initial bid for its assets. Read more ...

Regeneron's purchase is still subject to court ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

In the latest quarter, 21 analysts provided ratings for Regeneron Pharmaceuticals (NASDAQ:REGN), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview ...

You may also report side effects to Regeneron Pharmaceuticals at 1-877-542-8296. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life ...

President and Chief Scientific Officer at Regeneron. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded ...

Regeneron will make an upfront payment to Hansoh ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals ... and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider ...